Gsa Capital Partners LLP Sangamo Therapeutics, Inc Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 345,632 shares of SGMO stock, worth $743,108. This represents 0.02% of its overall portfolio holdings.
Number of Shares
345,632
Previous 933,176
62.96%
Holding current value
$743,108
Previous $334,000
10.48%
% of portfolio
0.02%
Previous 0.02%
Shares
22 transactions
Others Institutions Holding SGMO
# of Institutions
114Shares Held
57.4MCall Options Held
560KPut Options Held
1.15M-
Wasatch Advisors Inc Salt Lake City, UT19.4MShares$41.8 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.6MShares$20.6 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.85MShares$10.4 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$10.1 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.35MShares$5.06 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $337M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...